Journal
SPRINGERPLUS
Volume 5, Issue -, Pages -Publisher
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1186/s40064-016-2873-2
Keywords
Non-small cell lung cancer; Leptomeningeal metastasis; EGFR-TKIs
Categories
Funding
- Development Center for Medical Science and Technology National Health Commission of the People's Republic of China [W2012FZ120]
- Key Disciplines of Jiaxing (Oncology) [04-F-14]
- Science and Technology Projects of Jiaxing [2014AY21030-4]
- Innovation team of Lung Cancer in Early Diagnosis and Comprehensive Treatment
Ask authors/readers for more resources
Leptomeningeal metastasis (LM) is a terminal event in the development of non-small cell lung cancer (NSCLC). It has a poor prognosis with median survival of 1.9 months if untreated. The improvement of OS in NSCLC patients relatively increases incidence of LM. While current therapeutic options for LM are limited. Epidermal growth factor receptor-tyrosine kinase inhibitors are a class of small molecules and show dramatic response in epidermal growth factor receptor mutated patients. It also has a distinct therapeutic potential against brain metastases. Although there are some studies on EGFR-TKIs and brain metastases, the role of EGFR-TKIs on LM are not fully clarified. In this review, we will summarize current evidences concerning the use and discuss the role of EGFR-TKIs on LM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available